Details of the Drug Reposition

General Information of This Drug (ID: DMM0XGL)

Drug Name
Idarubicin   DMM0XGL
Synonyms
DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
5 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Leukemia DISNAKFL N.A. Approved [1]
Childhood acute megakaryoblastic leukemia DIS5VZDR N.A. Approved [1]
Adult acute monocytic leukemia DISG6BLX N.A. Approved [1]
Acute myelogenous leukaemia DISCSPTN 2A41 Approved [1]
Acute myeloid leukaemia DIS0BM1I 2A60 Approved [2]
------------------------------------------------------------------------------------
1 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Promyelocytic leukaemia DISYGG13 2A82.1 Discontinued in Phase 1 [3]
------------------------------------------------------------------------------------

References

1 Idarubicin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
3 Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery